Get the Stockscreener App
25.68
3.38%
0.84
Maze Therapeutics Inc stock is traded at $25.68, with a volume of 1.39M.
It is up +3.38% in the last 24 hours and up +4.82% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$24.84
Open:
$25.51
24h Volume:
1.39M
Relative Volume:
1.64
Market Cap:
$1.42B
Revenue:
$2.50M
Net Income/Loss:
$-131.12M
P/E Ratio:
-9.0324
EPS:
-2.8431
Net Cash Flow:
$-112.73M
1W Performance:
+6.60%
1M Performance:
+4.82%
6M Performance:
-36.78%
1Y Performance:
+128.06%
1-Day Range:
$24.95
$25.84
1-Week Range:
$23.50
$25.84
52-Week Range:
$9.83
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
25.68 | 1.42B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Buy |
| Mar-10-26 | Initiated | Mizuho | Outperform |
| Dec-04-25 | Initiated | Wells Fargo | Overweight |
| Nov-14-25 | Initiated | Raymond James | Outperform |
| Sep-02-25 | Initiated | BTIG Research | Buy |
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
View All
Maze Therapeutics Inc Stock (MAZE) Latest News
Maze Therapeutics Inc (MAZE) Institutional Confidence - TradingKey
Maze Therapeutics Inc (MAZE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maze Therapeutics Inc (MAZE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maze Therapeutics Inc (MAZE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Maze Therapeutics Inc (MAZE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MAZE Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressGuidance Revision Trend - newsline.com
Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk - Yahoo Finance
MAZE Q1 2026 Earnings: Narrower Loss Surprises Analysts Amid Pipeline ProgressEarnings Acceleration Picks - lwvtexas.org
Maze Therapeutics (MAZE) price target increased by 11.37% to 44.12 - MSN
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor - TipRanks
[Form 4] Maze Therapeutics, Inc. Insider Trading Activity - Stock Titan
Maze Therapeutics (MAZE) director receives grant of 18,000 stock options exercisable at $23.58 - Stock Titan
Director Richard Scheller receives 18,000 Maze Therapeutics (MAZE) stock options - Stock Titan
Maze Therapeutics (MAZE) director Herve Hoppenot awarded 18,000 stock options at $23.58 - Stock Titan
18,000 Maze Therapeutics (MAZE) options granted to director Andrews - Stock Titan
Maze Therapeutics (MAZE) shareholders elect directors and ratify Ernst & Young - Stock Titan
MAZE: Lead assets show strong efficacy and safety, with pivotal trials and key data readouts set for 2026–2027 - TradingView
MAZE: Directors and auditor ratified by majority vote; no shareholder questions submitted - TradingView
MAZE: Both director nominees and the auditor appointment were approved by majority vote - TradingView
MAZE Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockBasic EPS Analysis - newsline.com
Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now - Insider Monkey
Maze Therapeutics CEO Sells Shares Worth Around 847000 Dollars - HarianBasis.co
8 Oversold Stocks to Buy Right Now - insidermonkey.com
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? - Yahoo Finance
Maze Therapeutics president sells $381k in common stock By Investing.com - Investing.com Australia
Maze Therapeutics president sells $381k in common stock - Investing.com
Maze Therapeutics (MAZE) CEO’s family trusts sell 6,643 shares - Stock Titan
Maze Therapeutics (MAZE) CMO sells 14,853 shares after option exercise - Stock Titan
Maze Therapeutics to Participate in Two Upcoming Investor Conferences - 富途牛牛
Maze Therapeutics (MAZE) CSBO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
Why Is Maze Therapeutics, Inc. (MAZE) Stock Down Today? - Meyka
Coloma trusts sell MAZE shares (MAZE) under Rule 144 notice - Stock Titan
Maze Therapeutics (MAZE) Edges Higher, Consolidating Between Support and ResistanceEarnings Miss Risk - The Legal Advocate
Maze Therapeutics Inc. (MAZE) Edges Higher, Tests Key Resistance ZoneRisk Reversal - newsline.com
Maze Therapeutics (MAZE) Edges Higher: Biotech Stock Tests Key Technical LevelsHagopian Line - The Legal Advocate
Maze Therapeutics (MAZE) Edges Higher With Support Holding FirmSocial Sentiment - newsline.com
Maze Therapeutics to Present at William Blair and Goldman Sachs Healthcare Conferences in June 2024 - geneonline.com
Watch Maze Therapeutics CEO at Jefferies and Goldman health conferences in June - Stock Titan
J.P. Morgan Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Cuts Target Price to $53 - Moomoo
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - AOL.com
Maze Therapeutics, Inc. Files Form 8-K with SEC: Company Details, Nasdaq Listing, and Contact Information - Minichart
Maze Therapeutics Analyst Ratings and Price Targets | NASDAQ:MAZE - Benzinga
Maze Therapeutics CFO Expands Role Amid Finance Leadership Change - TipRanks
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Protara Therapeutics (TARA) - The Globe and Mail
H.C. Wainwright Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $110 - Moomoo
100% Of This Maze Therapeutics Insider's Holdings Were Sold - 富途牛牛
Maze Therapeutics CEO Jason Coloma sells $50,388 in stock By Investing.com - Investing.com Australia
Maze Therapeutics Insider Sold Shares Worth $393,354, According to a Recent SEC Filing - Moomoo
Maze Therapeutics CEO Jason Coloma sells $50,388 in stock - Investing.com
Maze Therapeutics Inc Stock (MAZE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):